ARQT vs ERAS: stock comparison and AI forecast
Arcutis Biotherapeutics, Inc. (ARQT) and Erasca, Inc. (ERAS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ARQT Arcutis Biotherapeutics, Inc.
- Market Cap
- $3.39B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
ERAS Erasca, Inc.
- Price
- $13.27 +27.6% · 6M
- Market Cap
- $4.64B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ERAS is 1.4 times larger than ARQT by market capitalization ($4.64B against $3.39B).
- ARQT carries 1.15 times debt per unit of equity, against 0.20 times for ERAS.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ARQT | ERAS |
|---|---|---|
| Market Cap | $3.39B | $4.64B |
| P/B Ratio | 13.91x | 12.83x |
| EPS | $-0.13 | $-0.46 |
| Book Value/Share | $1.94 | $1.03 |
| Revenue/Share | $4.05 | – |
| FCF/Share | $0.48 | $-0.28 |
Profitability & Margins
| Metric | ARQT | ERAS |
|---|---|---|
| ROIC | 10.0% | -75.4% |
| Gross Margin | 91.2% | – |
| Operating Margin | 6.9% | – |
| EBT Margin | 6.4% | – |
| Tax Rate | 2.8% | – |
Financial Health
| Metric | ARQT | ERAS |
|---|---|---|
| Current Ratio | 2.92x | 8.29x |
| Quick Ratio | 2.66x | – |
| D/E Ratio | 1.15x | 0.20x |
| Financial Leverage | 2.15x | 1.20x |
| Interest Coverage | 3.8x | – |
| Working Capital | $331M | $245M |
Cash Flow
| Metric | ARQT | ERAS |
|---|---|---|
| Operating Cash Flow | $60M | -$98M |
| Free Cash Flow | $60M | -$98M |
| Capital Spending | -$260K | -$60K |
| FCF/Sales | 11.7% | – |
| CapEx/Sales | 0.1% | – |
Operational Efficiency
| Metric | ARQT | ERAS |
|---|---|---|
| Asset Turnover | 0.97x | – |
| Receivables Turnover | 3.0x | – |
| Inventory Turnover | 1.0x | – |
| Fixed Assets Turnover | 639.0x | – |
| Days Sales Outstanding | 123 days | – |
| Days Inventory | 371 days | – |
| Payables Period | 68 days | – |
| Cash Conversion Cycle | 427 days | – |
Income Statement
| Metric | ARQT | ERAS |
|---|---|---|
| Total Revenue | $509M | – |
| Operating Income | $35M | -$303M |
| R&D Expense | $94M | $109M |
| SG&A Expense | $335M | – |
| Cost of Goods Sold | $45M | – |
Dividend & Shareholder Information
| Metric | ARQT | ERAS |
|---|---|---|
| Shares Outstanding | 126M | 350M |
ARQT vs ERAS: stock comparison and AI forecast
Which is bigger, ARQT or ERAS?
ERAS is 1.4 times larger than ARQT by market capitalization ($4.64B against $3.39B).
Which one does Intratio's AI model rank higher, ARQT or ERAS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.